Array BioPharma’s ARRY-797 Meets Primary Endpoint in Clinical Proof of Concept Trial in Osteoarthritis Patients Whose Pain is Poorly Controlled by NSAIDs Array BioPharma (NASDAQ: ARRY) today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback